Browsing tag
Zimbabweans living with HIV and on the Second regimen of the antiretroviral may be forced to default or change one of their drugs following an announcement that there is a nationwide shortage of second line medication.
The United States (US) has supplied Zimbabwe with 2,1 million bottles of Dolutegravir (DTG), a new antiretroviral drug which is more effective in viral suppression and has fewer side effects than Efavirenz.
Newly diagnosed HIV patients are now being initiated onto a new regimen of antiretroviral medication containing Dolutegravir (DTG), a drug which has significantly less side effects and is more affordable compared to the current line.
Government has deferred the national rollout of dolutegravir, an anti-retroviral drug, to adolescent girls and women of child-bearing age, following reports from Botswana that the drug was associated with birth deformities in infants born to HIV-positive mothers taking the drug at the time of conception.